Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Not just genomewide association studies: rare variants in genes not identified through genomewide association studies also contribute to hypertriglyceridemia.

Evans D, Diemert P.

Circ Cardiovasc Genet. 2012 Feb 1;5(1):5-6. doi: 10.1161/CIRCGENETICS.111.962548. No abstract available.

2.

A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network.

Aslibekyan S, Kabagambe EK, Irvin MR, Straka RJ, Borecki IB, Tiwari HK, Tsai MY, Hopkins PN, Shen J, Lai CQ, Ordovas JM, Arnett DK.

Pharmacogenet Genomics. 2012 Mar;22(3):191-7. doi: 10.1097/FPC.0b013e32834fdd41.

3.

The effect of CYP7A1 polymorphisms on lipid responses to fenofibrate.

Shen J, Arnett DK, Parnell LD, Lai CQ, Straka RJ, Hopkins PN, An P, Feitosa MF, Ordovás JM.

J Cardiovasc Pharmacol. 2012 Mar;59(3):254-9. doi: 10.1097/FJC.0b013e31823de86b.

4.

Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.

Brautbar A, Covarrubias D, Belmont J, Lara-Garduno F, Virani SS, Jones PH, Leal SM, Ballantyne CM.

Atherosclerosis. 2011 Dec;219(2):737-42. doi: 10.1016/j.atherosclerosis.2011.08.015. Epub 2011 Aug 22.

PMID:
21889769
5.

Genome-wide interaction-based association analysis identified multiple new susceptibility Loci for common diseases.

Liu Y, Xu H, Chen S, Chen X, Zhang Z, Zhu Z, Qin X, Hu L, Zhu J, Zhao GP, Kong X.

PLoS Genet. 2011 Mar;7(3):e1001338. doi: 10.1371/journal.pgen.1001338. Epub 2011 Mar 17.

6.

Lipoprotein association studies: taking stock and moving forward.

Talmud PJ, Yiannakouris N, Humphries SE.

Curr Opin Lipidol. 2011 Apr;22(2):106-12. doi: 10.1097/MOL.0b013e3283423f81. Review.

PMID:
21178771
7.

Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study.

Irvin MR, Kabagambe EK, Tiwari HK, Parnell LD, Straka RJ, Tsai M, Ordovas JM, Arnett DK.

Circ Cardiovasc Genet. 2010 Oct;3(5):462-7. doi: 10.1161/CIRCGENETICS.110.950667. Epub 2010 Aug 21.

8.

Biological, clinical and population relevance of 95 loci for blood lipids.

Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, Johansen CT, Fouchier SW, Isaacs A, Peloso GM, Barbalic M, Ricketts SL, Bis JC, Aulchenko YS, Thorleifsson G, Feitosa MF, Chambers J, Orho-Melander M, Melander O, Johnson T, Li X, Guo X, Li M, Shin Cho Y, Jin Go M, Jin Kim Y, Lee JY, Park T, Kim K, Sim X, Twee-Hee Ong R, Croteau-Chonka DC, Lange LA, Smith JD, Song K, Hua Zhao J, Yuan X, Luan J, Lamina C, Ziegler A, Zhang W, Zee RY, Wright AF, Witteman JC, Wilson JF, Willemsen G, Wichmann HE, Whitfield JB, Waterworth DM, Wareham NJ, Waeber G, Vollenweider P, Voight BF, Vitart V, Uitterlinden AG, Uda M, Tuomilehto J, Thompson JR, Tanaka T, Surakka I, Stringham HM, Spector TD, Soranzo N, Smit JH, Sinisalo J, Silander K, Sijbrands EJ, Scuteri A, Scott J, Schlessinger D, Sanna S, Salomaa V, Saharinen J, Sabatti C, Ruokonen A, Rudan I, Rose LM, Roberts R, Rieder M, Psaty BM, Pramstaller PP, Pichler I, Perola M, Penninx BW, Pedersen NL, Pattaro C, Parker AN, Pare G, Oostra BA, O'Donnell CJ, Nieminen MS, Nickerson DA, Montgomery GW, Meitinger T, McPherson R, McCarthy MI, McArdle W, Masson D, Martin NG, Marroni F, Mangino M, Magnusson PK, Lucas G, Luben R, Loos RJ, Lokki ML, Lettre G, Langenberg C, Launer LJ, Lakatta EG, Laaksonen R, Kyvik KO, Kronenberg F, König IR, Khaw KT, Kaprio J, Kaplan LM, Johansson A, Jarvelin MR, Janssens AC, Ingelsson E, Igl W, Kees Hovingh G, Hottenga JJ, Hofman A, Hicks AA, Hengstenberg C, Heid IM, Hayward C, Havulinna AS, Hastie ND, Harris TB, Haritunians T, Hall AS, Gyllensten U, Guiducci C, Groop LC, Gonzalez E, Gieger C, Freimer NB, Ferrucci L, Erdmann J, Elliott P, Ejebe KG, Döring A, Dominiczak AF, Demissie S, Deloukas P, de Geus EJ, de Faire U, Crawford G, Collins FS, Chen YD, Caulfield MJ, Campbell H, Burtt NP, Bonnycastle LL, Boomsma DI, Boekholdt SM, Bergman RN, Barroso I, Bandinelli S, Ballantyne CM, Assimes TL, Quertermous T, Altshuler D, Seielstad M, Wong TY, Tai ES, Feranil AB, Kuzawa CW, Adair LS, Taylor HA Jr, Borecki IB, Gabriel SB, Wilson JG, Holm H, Thorsteinsdottir U, Gudnason V, Krauss RM, Mohlke KL, Ordovas JM, Munroe PB, Kooner JS, Tall AR, Hegele RA, Kastelein JJ, Schadt EE, Rotter JI, Boerwinkle E, Strachan DP, Mooser V, Stefansson K, Reilly MP, Samani NJ, Schunkert H, Cupples LA, Sandhu MS, Ridker PM, Rader DJ, van Duijn CM, Peltonen L, Abecasis GR, Boehnke M, Kathiresan S.

Nature. 2010 Aug 5;466(7307):707-13. doi: 10.1038/nature09270.

9.

Investigation of variants identified in caucasian genome-wide association studies for plasma high-density lipoprotein cholesterol and triglycerides levels in Mexican dyslipidemic study samples.

Weissglas-Volkov D, Aguilar-Salinas CA, Sinsheimer JS, Riba L, Huertas-Vazquez A, Ordoñez-Sánchez ML, Rodriguez-Guillen R, Cantor RM, Tusie-Luna T, Pajukanta P.

Circ Cardiovasc Genet. 2010 Feb;3(1):31-8. doi: 10.1161/CIRCGENETICS.109.908004. Epub 2009 Dec 11.

10.

Cardiovascular pharmacogenomics and individualized drug therapy.

Pereira NL, Weinshilboum RM.

Nat Rev Cardiol. 2009 Oct;6(10):632-8. doi: 10.1038/nrcardio.2009.154. Epub 2009 Aug 25. Review.

11.

PXR agonism decreases plasma HDL levels in ApoE3-Leiden.CETP mice.

de Haan W, de Vries-van der Weij J, Mol IM, Hoekstra M, Romijn JA, Jukema JW, Havekes LM, Princen HM, Rensen PC.

Biochim Biophys Acta. 2009 Mar;1791(3):191-7. doi: 10.1016/j.bbalip.2008.12.008. Epub 2008 Dec 25.

PMID:
19150509
12.

Common variants at 30 loci contribute to polygenic dyslipidemia.

Kathiresan S, Willer CJ, Peloso GM, Demissie S, Musunuru K, Schadt EE, Kaplan L, Bennett D, Li Y, Tanaka T, Voight BF, Bonnycastle LL, Jackson AU, Crawford G, Surti A, Guiducci C, Burtt NP, Parish S, Clarke R, Zelenika D, Kubalanza KA, Morken MA, Scott LJ, Stringham HM, Galan P, Swift AJ, Kuusisto J, Bergman RN, Sundvall J, Laakso M, Ferrucci L, Scheet P, Sanna S, Uda M, Yang Q, Lunetta KL, Dupuis J, de Bakker PI, O'Donnell CJ, Chambers JC, Kooner JS, Hercberg S, Meneton P, Lakatta EG, Scuteri A, Schlessinger D, Tuomilehto J, Collins FS, Groop L, Altshuler D, Collins R, Lathrop GM, Melander O, Salomaa V, Peltonen L, Orho-Melander M, Ordovas JM, Boehnke M, Abecasis GR, Mohlke KL, Cupples LA.

Nat Genet. 2009 Jan;41(1):56-65. doi: 10.1038/ng.291. Epub 2008 Dec 7.

13.

Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study.

Liu Y, Ordovas JM, Gao G, Province M, Straka RJ, Tsai MY, Lai CQ, Zhang K, Borecki I, Hixson JE, Allison DB, Arnett DK.

Pharmacogenet Genomics. 2009 Feb;19(2):161-9. doi: 10.1097/FPC.0b013e32831e030e.

14.

The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment.

Smith JA, Arnett DK, Kelly RJ, Ordovas JM, Sun YV, Hopkins PN, Hixson JE, Straka RJ, Peacock JM, Kardia SL.

Eur J Hum Genet. 2008 May;16(5):603-13. doi: 10.1038/sj.ejhg.5202003. Epub 2008 Jan 23.

15.

Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression.

van der Hoogt CC, de Haan W, Westerterp M, Hoekstra M, Dallinga-Thie GM, Romijn JA, Princen HM, Jukema JW, Havekes LM, Rensen PC.

J Lipid Res. 2007 Aug;48(8):1763-71. Epub 2007 May 24.

16.

The -256T>C polymorphism in the apolipoprotein A-II gene promoter is associated with body mass index and food intake in the genetics of lipid lowering drugs and diet network study.

Corella D, Arnett DK, Tsai MY, Kabagambe EK, Peacock JM, Hixson JE, Straka RJ, Province M, Lai CQ, Parnell LD, Borecki I, Ordovas JM.

Clin Chem. 2007 Jun;53(6):1144-52. Epub 2007 Apr 19.

17.

Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy.

Schmitz G, Schmitz-Madry A, Ugocsai P.

Curr Opin Lipidol. 2007 Apr;18(2):164-73. Review.

PMID:
17353665
18.
19.

Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes.

Foucher C, Rattier S, Flavell DM, Talmud PJ, Humphries SE, Kastelein JJ, Ayyobi A, Pimstone S, Frohlich J, Ansquer JC, Steiner G; DAIS investigators..

Pharmacogenetics. 2004 Dec;14(12):823-9.

PMID:
15608561
20.

Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans.

Cordell HJ.

Hum Mol Genet. 2002 Oct 1;11(20):2463-8. Review.

PMID:
12351582

Supplemental Content

Support Center